In addition, that EO but not EP HRT use appeared to be strongly protective against leptin SNP-associated CRC risk in our study aligns with prior evidence for repression of estrogen-stimulated ER activity by liganded progestin receptor [65]. The gene discussed is ESR1; the disease is colorectal carcinoma.